Rein Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $68.0M
- Price
- $0.7887
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.40%
- Volume
- 447.0K
About
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Quick stats
Shares outstanding86.3M
Computed float86.2M
Float / shares99.9%
Cash runway (months)20.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001420565
Websitehttp://www.reintx.com
AI Summary
AI-generated1/13
minorneutralclinical trial
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
Rein Therapeutics will present a late-breaking poster on inhaled LTI-03 in idiopathic pulmonary fibrosis at the European Respiratory Society 2026 Congress in Barcelona, running September 5-9, 2026.
The poster (PA6217, September 8 session on immunological mechanisms in pulmonary fibrosis) will be presented by Professor Philip Molyneaux of Imperial College London, and the underlying data has already been published in Nature Communications.
LTI-03 is a first-in-class inhaled peptide therapy derived from Caveolin-1 biology with U.S. Orphan Drug and Fast Track designations, and it is being tested in the randomized, placebo-controlled Phase 2 RENEW trial (NCT06968845).
RENEW is expected to enroll roughly 120 patients across the U.S., U.K., Australia, Poland, and Germany, with safety through Week 24 as the primary endpoint and change in forced vital capacity as the efficacy endpoint.